Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Pediatric Neurology

Standard of Care Treatment

At a Glance

SPG89 has no treatment that corrects the underlying genetic change, so care focuses on preserving a child’s movement and comfort. A coordinated team may use physical therapy, stretching, mobility aids, spasticity medicines, injections, and selected advanced procedures.

Managing SPG89 requires a comprehensive, proactive approach centered on supporting your child’s mobility and comfort. Because there is currently no cure that addresses the genetic mutation itself, the care is focused on symptomatic treatment—addressing the effects of the condition as they appear [1].

The primary goal of treatment is to maintain function, prevent permanent muscle shortening (contractures), and improve your child’s quality of life [1][2]. Because SPG89 is a lifelong, slowly progressive condition, the care plan must evolve as your child grows and their needs change [1].

A Multidisciplinary Care Team

No single doctor can manage SPG89 alone. Standard care involves a “multidisciplinary” team of specialists who coordinate their efforts to address the different ways the condition affects the body [1][3]. This team typically includes:

  • Pediatric Neurologist or Neurogeneticist: Often the “lead” doctor who manages the overall diagnosis and neurological monitoring [3].
  • Physical Medicine and Rehabilitation (PM&R) Physician: Also known as a physiatrist, this specialist focuses on function and manages spasticity treatments like medications or injections [1].
  • Physical and Occupational Therapists: The experts who work directly with your child on movement, balance, and daily living skills [4].
  • Orthopedic Surgeon: Monitors bone alignment and joint health, particularly in the hips and feet, and can perform surgery if muscles become too tight to allow movement [1].
  • Urologist: Monitors bladder health, as the nerves controlling the bladder can be affected by the same processes that impact the legs [1][5].

The Foundation: Physical Therapy and Stretching

Physical therapy (PT) is an important part of the long-term management plan for SPG89 [1][4]. It is not a “quick fix” but a continuous effort to keep the muscles as flexible and functional as possible.

  • Daily Stretching: Regular, individualized stretching is commonly recommended to combat the constant “pull” of spasticity [4][1]. This helps prevent contractures, where a joint becomes permanently stuck in a bent position because the muscle has shortened [1]. However, tone can sometimes help a weak child stand or walk, and overtreatment of stiffness can unmask weakness or increase fatigue.
  • Strength and Balance: While the muscles are stiff, they can also be weak. PT focuses on strengthening the “opposite” muscles to help balance the body and improve stability [4][6].
  • Robot-Assisted and Hydrotherapy: Some specialized centers use robot-assisted gait training or therapy in water (hydrotherapy) to help children practice walking in a supported environment [7][4].
  • Orthotics and Mobility Aids: Braces (such as Ankle-Foot Orthoses or AFOs) are often used to keep the feet in the right position and prevent toe-walking [8]. Walkers or crutches may be introduced to help with balance and allow for safer, longer-distance mobility [9].

Medical Management of Spasticity

When stretching and PT are not enough to manage the stiffness, doctors may use medications to help relax the muscles.

Oral Medications

Oral antispasmodics, such as baclofen or tizanidine, are often the first medications tried [10]. These drugs work on the central nervous system to reduce the overall level of muscle “tone” or stiffness throughout the body [10]. However, they can cause side effects like sedation, dizziness, hypotension, or increased weakness; tizanidine may require liver monitoring. Many children stop taking oral baclofen over time because of side effects or because it doesn’t provide enough benefit for their specific walking goals [10]. Crucially, baclofen must not be stopped abruptly, as sudden withdrawal can be dangerous.

Botulinum Toxin Injections

For stiffness that is concentrated in specific muscles (like the calves or inner thighs), botulinum toxin A (BoNT-A) injections may be used [11]. These injections temporarily “block” the signal from the nerve to the muscle, allowing the muscle to relax for several months, though they can also cause focal or generalized weakness [12].
Injections are typically paired with daily stretching and PT [13][14]. The injection creates a “window of opportunity” where the muscle is loose enough to be stretched and strengthened more effectively [13].

Advanced Interventions

In cases where spasticity is severe, progressive, or interfering with comfort and care, more advanced options may be considered, though evidence in SPG89 is very limited and often extrapolated from broader HSP or cerebral palsy cases.

Intrathecal Baclofen (ITB)

An ITB pump is a small device surgically placed under the skin of the abdomen that delivers baclofen directly into the fluid surrounding the spinal cord [15]. Because the medication goes directly to the nerves, much smaller doses are needed than with oral pills, which may help some patients avoid severe drowsiness [15][16]. However, ITB carries significant risks including pump or catheter complications, infection, overdose, life-threatening withdrawal, and possible walking-worsening risks. Before a pump is permanently placed, children usually undergo a “test dose” to see if the reduction in stiffness actually improves their movement [17].

Selective Dorsal Rhizotomy (SDR)

SDR is a specialized, irreversible neurosurgery that involves cutting some of the sensory nerve fibers in the spinal cord that are sending “misfired” signals to the leg muscles [18]. In carefully selected children with HSP—especially those who are still able to walk but are struggling with progressive stiffness—SDR has been studied for its potential to reduce spasticity and, in some cases, improve walking ability [15][18].

However, because SPG89 is a progressive condition, the decision to undergo SDR is complex. While the surgery can remove the spasticity, it cannot stop the underlying genetic process. It requires an intensive commitment to post-surgical rehabilitation, can irreversibly unmask underlying weakness, and is not an established standard treatment for SPG89 [15][19]. Your multidisciplinary team will help you weigh whether your child’s specific symptoms and goals make them a good candidate for these more permanent interventions [20].

Common questions in this guide

What does standard treatment for SPG89 involve?
There is currently no treatment that corrects the genetic change in SPG89. Care is individualized and usually combines a coordinated specialist team with physical therapy, stretching, mobility supports, and medicines or procedures to preserve function, prevent permanent muscle shortening, and improve comfort.
Which specialists usually care for a child with SPG89?
Care may involve a pediatric neurologist or neurogeneticist, a physical medicine and rehabilitation physician, physical and occupational therapists, an orthopedic surgeon, and a urologist. A coordinated team can monitor movement, muscle stiffness, bone and joint health, bladder function, and changing mobility goals.
How can physical therapy help a child with SPG89?
Physical therapy may include individualized stretching, strengthening, balance work, and supported walking practice to maintain flexibility and function. Braces, walkers, or crutches may also improve positioning and safer mobility. Because some muscle tone can help a weak child stand or walk, too much treatment may reveal weakness or increase fatigue.
What medicines are used for SPG89 muscle stiffness?
Doctors may use oral baclofen or tizanidine to reduce widespread muscle stiffness, but these medicines can cause sleepiness, dizziness, low blood pressure, or increased weakness. Tizanidine may require liver monitoring. Baclofen must not be stopped suddenly because withdrawal can be dangerous.
Can botulinum toxin injections help with SPG89 spasticity?
Botulinum toxin A may temporarily relax selected muscles, such as the calves or inner thighs, when stiffness is concentrated in those areas. The effect usually lasts for several months and is paired with stretching and physical therapy, but focal or generalized weakness is possible.
When might an intrathecal baclofen pump or selective dorsal rhizotomy be considered?
These advanced options may be discussed when spasticity is severe, progressive, or interfering with comfort and care, but evidence specific to SPG89 is limited. An intrathecal baclofen pump has risks such as infection, device problems, overdose, and dangerous withdrawal. Selective dorsal rhizotomy is irreversible, requires intensive rehabilitation, can uncover weakness, and does not stop the underlying genetic process.

Get notified when new evidence is published on spastic paraplegia 89, autosomal recessive.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.

    Mania-Pâris L, Ewenczyk C, Nicolas G, et al.

    Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.

    PMID: 40450402
  2. 2

    Management of Hereditary Spastic Paraplegia: A Systematic Review of the Literature.

    Bellofatto M, De Michele G, Iovino A, et al.

    Frontiers in neurology 2019; (10()):3 doi:10.3389/fneur.2019.00003.

    PMID: 30723448
  3. 3

    Hereditary spastic paraplegia: a practical approach.

    Bradley M, Kalfat A, Walsh RA, et al.

    Practical neurology 2026; doi:10.1136/pn-2026-005344.

    PMID: 42816178
  4. 4

    The therapeutic effects of physical treatment for patients with hereditary spastic paraplegia: a narrative review.

    Di Ludovico A, Ciarelli F, La Bella S, et al.

    Frontiers in neurology 2023; (14()):1292527 doi:10.3389/fneur.2023.1292527.

    PMID: 38093754
  5. 5

    Non-motor symptoms are relevant and possibly treatable in hereditary spastic paraplegia type 4 (SPG4).

    Rattay TW, Boldt A, Völker M, et al.

    Journal of neurology 2020; (267(2)):369-379 doi:10.1007/s00415-019-09573-w.

    PMID: 31646384
  6. 6

    Pathophysiology, diagnostic work-up and management of balance impairments and falls in patients with hereditary spastic paraplegia.

    Nonnekes J, van Lith B, van de Warrenburg BP, et al.

    Journal of rehabilitation medicine 2017; (49(5)):369-377 doi:10.2340/16501977-2227.

    PMID: 28471471
  7. 7

    "Effects of robot-assisted gait training combined with traditional treatment in hereditary spastic paraplegia: An observational pilot cohort study".

    Diella E, Malerba G, Biffi E, et al.

    Scientific reports 2026; (16(1)).

    PMID: 42265415
  8. 8

    Gait Training for Walking Acquisition in a Child with Hereditary Spastic Paraplegia: A Case Report.

    Abe H, Hanamachi M

    Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association 2025; (37(3)):390-395 doi:10.1097/PEP.0000000000001208.

    PMID: 40227975
  9. 9

    Walking aids to improve gait in hereditary spastic paraplegia - effects and predictive parameters in a short-term sensor-based evaluation.

    Kotter K, Ibrahim A, Koch V, et al.

    Neurodegenerative disease management 2026; 1-11 doi:10.1080/17582024.2026.2713717.

    PMID: 42558011
  10. 10

    Rehabilitation management of children with hereditary spastic paraplegia: a retrospective cohort study.

    Paget SP, McIntyre S, Lewis J, et al.

    Developmental neurorehabilitation 2026; 1-8 doi:10.1080/17518423.2026.2738682.

    PMID: 42831377
  11. 11

    Efficacy of a Combined Treatment of Botulinum Toxin and Intensive Physiotherapy in Hereditary Spastic Paraplegia.

    Paparella G, Vavla M, Bernardi L, et al.

    Frontiers in neuroscience 2020; (14()):111 doi:10.3389/fnins.2020.00111.

    PMID: 32153352
  12. 12

    Mobile digital gait analysis captures effects of botulinum toxin in hereditary spastic paraplegia.

    Ibrahim AA, Ollenschläger M, Klebe S, et al.

    European journal of neurology 2024; (31(8)):e16367 doi:10.1111/ene.16367.

    PMID: 38859620
  13. 13

    Functional effects of botulinum toxin type-A treatment and subsequent stretching of spastic calf muscles: a study in patients with hereditary spastic paraplegia.

    de Niet M, de Bot ST, van de Warrenburg BP, et al.

    Journal of rehabilitation medicine 2015; (47(2)):147-53 doi:10.2340/16501977-1909.

    PMID: 25325386
  14. 14

    Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia.

    van Lith BJH, den Boer J, van de Warrenburg BPC, et al.

    Journal of rehabilitation medicine 2019; (51(6)):434-441 doi:10.2340/16501977-2556.

    PMID: 30968942
  15. 15

    Surgical treatment options for spasticity in children and adolescents with hereditary spastic paraplegia.

    van de Pol LA, Burgert N, van Schie PEM, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(3)):855-861 doi:10.1007/s00381-023-06159-w.

    PMID: 37783799
  16. 16

    Intrathecal baclofen for the management of hereditary spastic paraparesis: a systematic review.

    Viana Pinto L, Romeiro I, Gouveia F, et al.

    International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation 2024; (47(1)):3-9 doi:10.1097/MRR.0000000000000607.

    PMID: 38251093
  17. 17

    The use of intrathecal baclofen for management of spasticity in hereditary spastic paraparesis: A case series.

    Pointon R, Whelan H, Raza R, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2022; (36()):14-18 doi:10.1016/j.ejpn.2021.11.003.

    PMID: 34794088
  18. 18

    Selective Dorsal Rhizotomy in Children with Hereditary Spastic Paraplegia.

    Stanton AN, Fredricks NS, Price AM, et al.

    Pediatric neurosurgery 2026; 1-8 doi:10.1159/000551915.

    PMID: 41961756
  19. 19

    Selective dorsal rhizotomy for hereditary spastic paraparesis in children.

    Sharma J, Bonfield C, Steinbok P

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2016; (32(8)):1489-94 doi:10.1007/s00381-016-3122-2.

    PMID: 27312078
  20. 20

    Preoperative gait pattern as predictor of gait changes following selective dorsal rhizotomy.

    van Dijk LMM, Veerkamp K, van der Krogt MM, et al.

    Gait & posture 2025; (117()):363-371 doi:10.1016/j.gaitpost.2025.01.017.

    PMID: 39889620

This page explains treatment approaches for children with SPG89 for informational purposes only and does not constitute medical advice. Your child's multidisciplinary team should tailor therapy, medicines, and procedures to the child's strength, goals, and risks.